Impotence Is Not Inevitable After Prostate Cancer Treatment

Treatment of metastatic prostate cancer after STAMPEDE

tau.amegroups.com © Translational Andrology and Urology. All rights reserved. Over decades, long-term hormone therapy has been considered as the standard of care (SOC) for men with advanced prostate cancer. The problem is that several months after the commencement of treatment, tumors become castration-resistant and virtually all patients show disease progression. In 2004, two randomized Phase ...

Urinary incontinence after treatment for prostate cancer.

Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer

Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...

Therapy of Treatment Failure After Curative Treatment of Prostate Cancer

Objective: Recurrence rates of 40–60% after percutaneous radiotherapy or brachytherapy and 20–40% after prostatectomy are described. This review will discuss curative treatment options for salvage after primary therapy. Methods: Relevant information was identified through searches of published studies, abstracts from scientific meetings, and review articles. Results: Clinical experience in salv...

Pain may be inevitable; inadequate management is not

Assessing and managing pain in the critically ill patient is challenging. Reproducible and clinically applicable pain measurement scales have yet to be validated and ubiquitously applied in the intensive care unit setting. Critical care clinicians, both physicians and nurses, should thoughtfully monitor their patient's pain level, periodically reassess their practice and critically evaluate the...